Franziskus Hospital Harderberg
- Address
- lock Available on a paid plan
Franziskus Hospital Harderberg - Advanced Oncology Research Center
Franziskus Hospital Harderberg is a leading clinical research institution specializing in cutting-edge oncology trials, with a particular emphasis on precision medicine and biomarker-driven therapy approaches. The center demonstrates extensive expertise in investigating novel targeted therapies and immunotherapies across multiple cancer types, with a strong focus on breast cancer, lung cancer, and hematologic malignancies.
- Breast Cancer Research: Comprehensive studies spanning triple-negative, HER2-positive, and hormone receptor-positive subtypes, including neoadjuvant and adjuvant trials with antibody-drug conjugates and CDK4/6 inhibitors
- Advanced Lung Cancer Programs: Extensive experience with EGFR-mutated and ALK-positive NSCLC, investigating targeted therapies including osimertinib, alectinib, and novel exon 20 insertion inhibitors
- Precision Oncology: Leadership in ctDNA-guided treatment strategies and molecular profiling for personalized therapeutic decisions in both solid tumors and acute lymphoblastic leukemia
- Next-Generation Therapies: Active participation in trials evaluating antibody-drug conjugates (trastuzumab deruxtecan, sacituzumab govitecan, dato-DXd) and combination immunotherapy approaches
The center's research portfolio demonstrates particular strength in early-stage intervention studies and adjuvant therapy optimization, including innovative discontinuation trials for CDK4/6 inhibitors. With involvement in multiple phase III international trials and adaptive trial designs, Franziskus Hospital Harderberg contributes significantly to establishing new standards of care across gastrointestinal cancers, including colorectal cancer research and emerging biomarker-directed strategies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 83 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 82 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1AstraZeneca AB4active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Franziskus Hospital Harderberg
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease | Gilead Sciences Inc. | Phase III | Recruiting | Nov 2024 | — |
IMP list
lock Showing 1 of 83 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 16 | Unknown | 2018-06-13 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.